Human CellExp VEGF 121, Human recombinant protein
Human Cellexp Human Recombinant VEGF 121
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P15692 |
---|---|
Calculated MW | 37 kDa, homodimer; 50 kDa, homotrimer, glycosylated |
Gene ID | 7422 |
---|---|
Gene Symbol | VEGFA |
Other Names | Vascular endothelial growth factor A, VEGF-A, Vascular permeability factor, VPF, VEGF, MGC70609. |
Gene Source | Human |
Source | Human 293 cell expressed |
Assay&Purity | SDS-PAGE; > 95% |
Assay2&Purity2 | N/A; |
Recombinant | Yes |
Results | 2 to 8 ng/ml |
Application Notes | Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin. |
Format | Lyophilized |
Storage | -80°C; Lyophilized in PBS. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
VEGF is an important signaling protein involved in both vasculogenesis and angiogenesis. As its name implies, VEGF activity has been mostly studied on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g. stimulation monocyte/ macrophage migration, neurons, cancer cells, kidney epithelial cells).VEGF mediates increased vascular permeability, induces angiogenesis, vasculogenesis and endothelial cell growth, promotes cell migration, and inhibits apoptosis. In vitro, VEGF has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor. Elevated levels of this protein are linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy.
References
Leung D.W.,et al.Science 246:1306-1309(1989).
Keck P.J.,et al.Science 246:1309-1312(1989).
Tischer E.,et al.J. Biol. Chem. 266:11947-11954(1991).
Houck K.A.,et al.Mol. Endocrinol. 5:1806-1814(1991).
Weindel K.,et al.Biochem. Biophys. Res. Commun. 183:1167-1174(1992).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.